CLEW Medical has announced that Dr. John Halamka has joined its Scientific Advisory Board, enabling the company to benefit from his in-depth, leadership experience at the nexus of technology and healthcare.
Dr. Halamka currently serves as Executive Director of Beth Israel Lahey Health Technology Exploration Center. He also leads innovation for Beth Israel Lahey Health, serves as Chairman of the New England Healthcare Exchange Network (NEHEN), is the International Healthcare Innovation professor at Harvard Medical School, and is a practicing emergency physician. Previously, Dr. Halamka served as CIO of Beth Israel Deaconess Healthcare System.
CLEW’s AI-Machine Learning tools convert medical data into life-saving medical knowledge that can be used to reduce costs and improve clinical outcomes. Currently focused on critical care, CLEW’s machine learning predictive technology allows clinicians to benefit from proactive, predictive assessment, a more collaborative team approach and efficient clinical resource allocation. Dr. Halamka’s insights into largescale healthcare technology systems will assist CLEW as it expands its product offering to include all care settings.
Commenting on the announcement, Gal Salomon, CLEW’s CEO said, “It is a great privilege and vote of confidence to have someone of Dr. Halamka’s caliber join our Advisory Board. The Board plays a pivotal role in the company’s development, ensuring that our solutions deliver true patient value and can be fully integrated into the clinical workflow.”
The Chairman of the Scientific Advisory Board, Dr. James M. Blum, added, “CLEW’s vision is to deploy its AI-powered technology across the entire continuum of care. Dr. Halamka’s experience and hands-on knowledge about large-scale healthcare information systems are important additions to this effort. We look forward to collaborating with Dr. Halamka in shaping this vision.”
John Halamka added, “The volume and quality of patient data collected is increasing exponentially. I am honored to join the Scientific Advisory Board and I look forward to working with the CLEW team as they use AI and machine learning technologies to convert this data in actionable medical knowledge.”